STAT+: ARPA-H funds biotechs working on custom RNA therapies

Roche licenses a tri-specific antibody, new Trump deals may undercut its own goals, and other biotech news Adobe Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I was extremely confused when I saw a Spirit Halloween pop-up yesterday, but then realized October is indeed next month. Very spooky. The need-to-know this morning UniQure submitted applications to the FDA and the UK’s MHRA, seeking the marketing approval of AMT-130, its treatment for Huntington’s disease. New Trump deals may undercut efforts to lower costs The midterms are fast approaching, and President Trump hailed the new deals he struck with biopharma companies this week as part of his commitment to lowering drug costs. But in reality, the agreements may not amount to much, STAT’s John Wilkerson writes — and could even undercut the administration’s own efforts. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.